Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 570

1.

First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:32-8.

PMID:
16919008
2.

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.

Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:25-31.

PMID:
16919007
3.

Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.

D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.

Int J Cardiol. 2012 Mar 22;155(3):378-82. doi: 10.1016/j.ijcard.2010.10.051. Epub 2010 Nov 16.

PMID:
21081251
4.

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.

J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027.

5.

Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.

Garg N, Sharma MK, Sinha N.

Int J Cardiol. 2007 Sep 3;120(3):306-13. Epub 2006 Dec 15.

PMID:
17174417
7.
8.

[Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].

Jiménez López-Guarch C, Escribano Subias P, Tello de Meneses R, Delgado Jiménez JF, Sadia Pérez D, Velázquez Martín MT, Gómez Sánchez MA, Sáenz de la Calzada C.

Rev Esp Cardiol. 2004 Oct;57(10):946-51. Spanish.

9.

Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.

Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.

J Heart Lung Transplant. 2007 Apr;26(4):363-9. Epub 2007 Mar 2.

PMID:
17403478
10.

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.

Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.

Eur Respir J. 2007 Mar;29(3):469-75. Epub 2006 Nov 1.

11.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.

Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.

PMID:
20015974
12.

Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.

Douwes JM, Roofthooft MT, Van Loon RL, Ploegstra MJ, Bartelds B, Hillege HL, Berger RM.

Heart. 2014 Feb;100(3):224-30. doi: 10.1136/heartjnl-2013-304895.

PMID:
24390161
13.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
15.

Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.

Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.

Heart. 2007 Mar;93(3):350-4. Epub 2006 Sep 15.

16.

[Sildenafil therapy for pulmonary hypertension: a prospective study].

Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Cheng XS, Gu Q, Zhao ZH, Zeng WJ, Zhu F, He JG.

Zhonghua Jie He He Hu Xi Za Zhi. 2011 Jun;34(6):419-23. Chinese.

PMID:
21781512
17.
18.

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.

Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS.

Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7. Epub 2005 Mar 4.

PMID:
15750042
19.

Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.

Baptista R, Castro G, da Silva AM, Monteiro P, Providência LA.

Rev Port Cardiol. 2013 Feb;32(2):123-9. doi: 10.1016/j.repc.2012.02.023. Epub 2013 Jan 23.

PMID:
23351920
20.

Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.

Benza RL, Rayburn BK, Tallaj JA, Coffey CS, Pinderski LJ, Pamoukian SV, Bourge RC.

Chest. 2006 Apr;129(4):1009-15.

PMID:
16608951

Supplemental Content

Support Center